RxDoctor Payments Data

Tapan Mehta

Vascular Neurology · Hartford, CTNPI 1194169755

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (46.3%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by Medical Device Business Services, Inc. at 29.8% of the total. 2025 is the largest year on record at $67,922, more than ten times the $321 reported in 2020.

$99,075in general payments, 2019–2025

Across 136 payments — averaging $728.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medical Device Business Services, Inc.$30K
  • Balt USA, LLC$28K
  • Medtronic$26K
  • Microvention, Inc.$12K
  • Johnson & Johnson$1K
  • Scientia Vascular$800
  • plus $1K from 7 others
$61,647in research payments, 2019–2025

Across 29 payments — averaging $2125.76 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medical Device Business Services, Inc.$40K
  • Genentech, Inc.$22K

What the payments were for

  • Consulting fees$45,85046%
  • Speaking & faculty fees$29,98430%
  • Travel & lodging$17,58518%
  • Food & beverage$5,6566%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few vascular neurology providers in Connecticutto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$91,157
Medicare patients
121
Services billed
385

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BrilintaTicagrelor27$16,601

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBrilinta$105$16,60127 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few vascular neurology providers in Connecticuton file to place this against a meaningful peer group, so we don't.

Other vascular neurology in Hartford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →